Feature | Cardiac Imaging | March 18, 2019| By Greg Freiherr

Monday ACC 2019: How Interventionalists Can Keep From Missing Coronary Stenoses

Study Discussed at ACC19 Extends Value of iFR Technology 

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram. Results from an international study presented at #ACC19 show that pressure readings in coronary arteries may identify locations of stenoses remaining after cardiac cath interventions.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

Greg Freiherr

Greg Freiherr

As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the location of stenoses not resolved by initially performed percutaneous coronary interventions (PCIs) to relieve restricted blood flow.

According to results from an international study presented during the annual meeting (#ACC19) of the American College of Cardiology, as many as 25 percent of patients undergoing coronary interventions have unresolved stenoses in their coronary vessels. These stenoses may be caused by lesions that can be localized using a technology called iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve).

Invented by Justin Davies, Ph.D., a consultant cardiologist in the Division of Cardiology Cardiothoracic and Thoracic Surgery at Imperial College Healthcare NHS Trust in London, the iFR technology is already being used in cath labs around the world to determine the severity of coronary lesions. The international study, dubbed DEFINE PCI, whose results were presented at #ACC19, indicates that this technology can also be leveraged to determine the locations of stenoses that remain after initial PCI.

Use of the iFR technology for this purpose adds time to the intervention, but the patient deserves the extra effort, Davies said. “Doing the very, very best for our patients is really important,” he said, particularly considering that these patients have undergone the inconveniences and the radiation associated with PCI.

 

How iFR Can Be Used To Find Residual Lesions

Pressure sensors located at different points along the iFR wire may show differences in pressure.  These differentials may be apparent, when the wire is pulled back from the initial treatment site.  If the pressure drops, the interventionalist knows that residual stenosis lies somewhere between the two pressure sensors, Davies explained. The Philips Healthcare SyncVision iFR Co-registration maps the pressure readings onto the angiogram.

Patients may undergo PCI after complaining of angina, which may be caused by severe blood flow restrictions in the coronary arteries. The stenoses associated with angina reduce blood flow, causing ischemia in heart tissue. Under interventional X-ray guidance, clinicians maneuver a balloon catheter and coronary stent to the treatment area. These are then deployed in efforts to restore arterial blood flow.

“The pressure wire pullback (identifies) where in the artery there are still potential zones where we could be treating,” Davies told ITN and DAIC in an interview at Philips’ booth on the ACC exhibit floor.

 

Latest Study Identifies Further Value Of iFR

Conducted at major U.S. and European medical centers, the DEFINE PCI study showed that the positive effects of coronary interventions in patients suffering from coronary artery disease may be limited by residual lesions. The study suggests that patient outcomes might be improved if the locations of these residual stenoses could be determined.

Philips, which sponsored the DEFINE-PCI prospective study of 500 patients, has licensed the iFR technology from the Imperial College, Davies said. The study, which determined the utility of iFR readings in identifying the locations of these lesions, was conducted “to the very highest levels of integrity. I feel very confident to stand by the results,” he said, noting that the study was conducted by the U.S.-based Cardiovascular Research Foundation and involved prestigious medical facilities including those at the Imperial College in the United Kingdom, as well as Duke Clinical Research Institute and Columbia University Medical Center, both of which are in the U.S.

The DEFINE-PCI study also confirmed the results of past studies, namely the iFR-SWEDEHEART and DEFINE-FLAIR trials, which had determined that a substantial minority of patients undergoing cardiac cath interventions do not benefit as much as they could.  Results from the most recent study underscored the findings of these previous studies, emphasizing “that there is further room for improvement,” Davies said.

“What this means is that we could get even better blood flow down the vessel; we could have even better relief of angina symptoms,” he continued. “Ultimately the patient will be the big winner from this.”

 

Greg Freiherr is a contributing editor to Imaging Technology News (ITN). Over the past three decades, Freiherr has served as business and technology editor for publications in medical imaging, as well as consulted for vendors, professional organizations, academia, and financial institutions.

 

Related content:

iFR More Cost-Effective Than FFR in PCI Guidance, DAIC 

Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation

ACC 2018 Late-Breaking Trials, DAIC

Sunday ACC 2019: Mixed Reality Offers Advantages of Virtual and Augmented Realities

Two Technologies That Offer a Paradigm Shift in Medicine at HIMSS 2017 

VIDEO: Augmented Reality for Surgical Planning

VIDEO: Users Can Touch This Virtual Reality Heart

A 40,000 Foot View of Trends in Cardiology

Applications for Artificial Intelligence in Cardiovascular Imaging

Machine Learning Approaches in Cardiovascular Imaging

Technology Report: Artificial Intelligence (Video report published January 2019) 

PODCAST: Shortcomings of CTA in Cardiology

PODCAST: How Technology Is Changing Cardiology

ACC.19 Future Hub Hosts “Shark Tank” of Emerging Technologies In Cardiology

Related Content

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Overlay Init